You have 9 free searches left this month | for more free features.

Homoharringtonine

Showing 1 - 25 of 54

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Acute Myeloid Leukemia, Adult Trial in Hangzhou (cladribine + homoharringtonine + cytarabine)

Recruiting
  • Acute Myeloid Leukemia, Adult
  • cladribine + homoharringtonine + cytarabine
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Jun 13, 2023

Acute Myeloid Leukemia Trial in Suzhou (Venetoclax, Homoharringtonine, Cytarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Suzhou, Jiangsu, China
    Qiu Huiying
Mar 28, 2023

Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Mitoxantrone hydrochloride liposome injection
  • +3 more
  • (no location specified)
May 29, 2023

Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine Trial in Guangzhou (VEN

Recruiting
  • Venetoclax Combined With Azacitidine Plus Homoharringtonine
  • Venetoclax Combined With Azacitidine
  • VEN combined with azacitidine plus homoharringtonine
  • VEN combined with azacitidine
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 9, 2022

Acute Myeloid Leukemia Trial in Tianjin (Mitoxantrone HCl liposome injection, Cytarabine, Homoharringtonine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Mitoxantrone hydrochloride liposome injection
  • +3 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jul 1, 2023

Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

Not yet recruiting
  • Relapsed/Refractory AML
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 28, 2023

Acute Myeloid Leukemia Trial in NanJing (Homoharringtonine, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • NanJing, China
    Department of Hematology, Zhongda Hospital, Medical School of So
Sep 2, 2022

Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

Recruiting
  • Relapsed or Refractory Acute Myeloid Leukemia
  • Taiyuan, Shanxi, China
    Tao Wang
Feb 9, 2023

Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 2, 2021

Secondary Acute Myeloid Leukemia Trial in Nanjing (Venetoclax;Azacitidine;Homoharringtonine)

Recruiting
  • Secondary Acute Myeloid Leukemia
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Aug 21, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Completed
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Los Angeles, California
  • +28 more
Dec 1, 2021

Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

Completed
  • Chronic Myeloid Leukemia
  • Omacetaxine mepesuccinate
  • Los Angeles, California
  • +31 more
Nov 11, 2021

Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

Completed
  • Relapsed Acute Myeloid Leukemia
  • +3 more
  • VAH regimen
  • VEN+HMA regimen
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 8, 2022

Acute Myeloid Leukemia (AML) Trial in Chengdu (SKLB1028, Salvage Chemotherapy)

Recruiting
  • Acute Myeloid Leukemia (AML)
  • Chengdu, Sichuan, China
    West China hospital of Sichuan University
Nov 1, 2021

JMML Trial in Tianjin (Azacitidine and homoharringtonine)

Recruiting
  • JMML
  • Azacitidine and homoharringtonine
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital, Chinese Acade
Aug 6, 2020

Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy Trial in China (APG-2575, reduced-dose HHT, standard-dose HHT)

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukaemia
  • Myeloid Malignancy
  • Beijing, Beijing, China
  • +9 more
Jan 10, 2022

AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)

Unknown status
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
Dec 9, 2020

AML, FLT3-ITD Mutation Trial in Hong Kong (Sorafenib, Omacetaxine Mepesuccinate Injection)

Completed
  • AML
  • FLT3-ITD Mutation
  • Hong Kong, Hong Kong
    The University of Hong Kong
Mar 26, 2020

MDS, Chronic Myelomonocytic Leukemia-2, Secondary Acute Myeloid Leukemia Trial in Nanjing (unrelated umbilical cord blood)

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
  • unrelated umbilical cord blood
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Oct 16, 2022

Acute Myeloid Leukaemia; MDS;Chronic Myelomonocytic Leukemia Trial in Shenzhen (Azacytidine, HAG Regimen, Azacytidine)

Recruiting
  • Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Mar 14, 2022

CEBPA Double Mutation, Acute Myeloid Leukemia Trial in Tianjin (HAD induction with intermediate dose cytarabine)

Recruiting
  • CEBPA Double Mutation
  • Acute Myeloid Leukemia
  • HAD induction with intermediate dose cytarabine
  • Tianjin, Tianjin, China
    HBDH
Aug 5, 2021

Acute Myeloid Leukemia, Venetoclax Trial in Kunming (combination of venetoclax and HAA regimen)

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax
  • combination of venetoclax and HAA regimen
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
May 29, 2023

High Grade MDS Trial in Aurora (Omacetaxine, Azacitidine)

Recruiting
  • High Grade Myelodysplastic Syndromes
  • Aurora, Colorado
    Universtiy of Colorado Denver
Nov 17, 2022

Relapsed or Refractory Hematologic Malignancies Trial in Chicago (Omacetaxine, Venetoclax)

Recruiting
  • Relapsed or Refractory Hematologic Malignancies
  • Chicago, Illinois
    University of Illinois Cancer Center
Sep 27, 2022